Nuvalent Inc (NUVL) Appoints Christy Oliger to its Board
Get Alerts NUVL Hot Sheet
Join SI Premium – FREE
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of
"Christy's proven success in delivering new therapies to patients living with cancer strengthens our Board as we evolve from a development-stage company toward potential commercialization," said
"Nuvalent's pipeline reflects a focused and disciplined approach to drug development, grounded in rigorous science and a deep understanding of patient and physician needs," said
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vivos Therapeutics opens sleep center in Henderson, Nevada
- Increasing unusual call volume: CSGP ETH MUX OVV PR TECK WSC BRR MKC PSNL QSR SOLT BULL IONS ALLY RARE BITU CAPR
- Wingspire Equipment Finance closes $140M AI compute infrastructure deal
Create E-mail Alert Related Categories
Board Changes, Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share